Jump to content

Endo International: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Salient corporate info
Line 16: Line 16:


'''Endo International plc''' is a generics and specialty branded pharmaceutical company. It was created as a result of a [[management buyout]] from [[DuPont|DuPont Merck]] in 1997 led by Carol Ammon.<ref>{{cite news|last1=Schneiderman|first1=R.M.|title=Ammon Exits Endo|url=https://www.forbes.com/2007/04/09/ammon-endo-retirement-face-cx_rs_0409autofacesscan01.html|work=Forbes|date=9 April 2007|language=en}}</ref>
'''Endo International plc''' is a generics and specialty branded pharmaceutical company. It was created as a result of a [[management buyout]] from [[DuPont|DuPont Merck]] in 1997 led by Carol Ammon.<ref>{{cite news|last1=Schneiderman|first1=R.M.|title=Ammon Exits Endo|url=https://www.forbes.com/2007/04/09/ammon-endo-retirement-face-cx_rs_0409autofacesscan01.html|work=Forbes|date=9 April 2007|language=en}}</ref>

Endo is one of the companies named in lawsuits by the states of Ohio<ref>{{cite news|last1=Dwyer|first1=Colin|title=Ohio Sues 5 Major Drug Companies For 'Fueling Opioid Epidemic'|url=http://www.npr.org/sections/thetwo-way/2017/05/31/530929307/ohio-sues-5-major-drug-companies-for-fueling-opioid-epidemic|work=NPR Online|date=31 May 2017|language=en}}</ref>, Missouri and Mississippi<ref>{{cite news|last1=Raymond|first1=Nate|title=Missouri sues opioid manufacturers, joining two other U.S. states|url=https://www.reuters.com/article/us-missouri-opioids-idUSKBN19C1VK|work=Reuters|date=21 Jun 2017|language=en}}</ref> as responsible for the US [[opioid epidemic]]. Its [[Form 10-K|10-K]] statement <ref>{{cite web|title=Eondo Pharmaceuticals, FORM 10-K|url=http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzc2MDIxfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636290126913304041|date=31 Dec 2016|language=en}}</ref> indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly [[opioid]]s.

==Acquisitions==
==Acquisitions==


Line 29: Line 32:
In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.<ref>{{cite news | title=Endo to Purchase NuPahte for $150M+ | author=<!--staff--> | page=10 | work = [[Gen. Eng. Biotechnol. News]] | date=January 15, 2014 | department=News: Industry Watch | format=paper | volume=34 | issue=2 }}</ref> However, [[Teva Pharmaceutical Industries|Teva]] prevailed in this acquisition with a substantially higher bid.<ref>{{cite news | title=Teva Outbids Endo, Acquires NuPathe for $144M+ | department=News: Industry Watch | type=paper | work=[[Gen. Eng. Biotechnol. News]] | page=10 | date=February 15, 2014 | volume=34 | issue=4 }}</ref>
In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.<ref>{{cite news | title=Endo to Purchase NuPahte for $150M+ | author=<!--staff--> | page=10 | work = [[Gen. Eng. Biotechnol. News]] | date=January 15, 2014 | department=News: Industry Watch | format=paper | volume=34 | issue=2 }}</ref> However, [[Teva Pharmaceutical Industries|Teva]] prevailed in this acquisition with a substantially higher bid.<ref>{{cite news | title=Teva Outbids Endo, Acquires NuPathe for $144M+ | department=News: Industry Watch | type=paper | work=[[Gen. Eng. Biotechnol. News]] | page=10 | date=February 15, 2014 | volume=34 | issue=4 }}</ref>


==See Also==

* [[Opioid epidemic]]
==References==
==References==
{{reflist}}
{{reflist}}

Revision as of 11:56, 14 August 2017

Endo International plc
Company typePublic
Nasdaq: ENDP
S&P 400 Component
IndustryPharmaceutical
HeadquartersDublin, Ireland and Malvern, Pennsylvania, U.S.
Websitewww.endo.com

Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.[1]

Endo is one of the companies named in lawsuits by the states of Ohio[2], Missouri and Mississippi[3] as responsible for the US opioid epidemic. Its 10-K statement [4] indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.

Acquisitions

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[5] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[5]

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[6][7]

In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion.[8]

In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.[9]

Acquisition attempts

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.[10] However, Teva prevailed in this acquisition with a substantially higher bid.[11]

See Also

References

  1. ^ Schneiderman, R.M. (9 April 2007). "Ammon Exits Endo". Forbes.
  2. ^ Dwyer, Colin (31 May 2017). "Ohio Sues 5 Major Drug Companies For 'Fueling Opioid Epidemic'". NPR Online.
  3. ^ Raymond, Nate (21 Jun 2017). "Missouri sues opioid manufacturers, joining two other U.S. states". Reuters.
  4. ^ "Eondo Pharmaceuticals, FORM 10-K". 31 Dec 2016.
  5. ^ a b Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28.
  6. ^ Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". Wall Street Journal.
  7. ^ "Endo Health to Buy Specialty Drug Maker for $1.6 Billion". New York Times Dealbook. November 5, 2013.
  8. ^ "Endo Scores with $2.6B Offer for Auxilium, Which Ends QLT Deal | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN". GEN. October 9, 2014.
  9. ^ Bray, Chad (18 May 2015). "Endo International to Pay $8.05 Billion for Par Pharmaceutical". The New York Times.
  10. ^ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News. Vol. 34, no. 2. January 15, 2014. p. 10. {{cite news}}: |format= requires |url= (help)
  11. ^ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 10.
  • Official website
  • Business data for Endo International plc:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Endo_International&oldid=795465883"